Medicenna Therapeutics (TSX:MDNA) - Aktienkurs, Nachrichten und Analyse

MDNA Aktienübersicht

Medicenna Therapeutics Corp. ist ein Immuntherapie-Unternehmen, das sich mit der Entwicklung und Vermarktung von Superkines und verstärkten Superkines für die Behandlung von Krebs und anderen Krankheiten beschäftigt. Mehr Details

MDNA grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	1/6
Künftiges Wachstum	2/6
Vergangene Leistung	0/6
Finanzielle Gesundheit	6/6
Dividenden	0/6

Belohnungen

Prognostiziertes jährliches Umsatzwachstum 72.3%

Risikoanalyse

Erzielt weniger als 1 Million USD an Einnahmen (CA$0)

Die Aktionäre wurden im vergangenen Jahr verwässert

Hat keine nennenswerte Marktkapitalisierung (CA$123M)

Derzeit unrentabel und in den nächsten 3 Jahren nicht rentabel zu werden prognostiziert

Medicenna Therapeutics Corp. Wettbewerber

Oncolytics Biotech

TSX:ONC

CA$102.5m

Covalon Technologies

TSXV:COV

CA$103.8m

Satellos Bioscience

TSX:MSCL

CA$85.2m

Eupraxia Pharmaceuticals

TSX:EPRX

CA$174.9m

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Medicenna Therapeutics
Historische Aktienkurse
Aktueller Aktienkurs	CA$1.57
52-Wochen-Hoch	CA$2.98
52-Wochen-Tief	CA$0.38
Beta	1.19
11 Monat Veränderung	-33.19%
3 Monate Veränderung	-27.31%
1 Jahr Veränderung	230.53%
33 Jahre Veränderung	-35.39%
5 Jahre Veränderung	16.30%
Veränderung seit IPO	-41.85%

Aktuelle Nachrichten und Updates

Recent updates

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Oct 18

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Jun 14

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Feb 28

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Nov 08

Is Medicenna Therapeutics (TSE:MDNA) In A Good Position To Deliver On Growth Plans?

Mar 01

Aktionärsrenditen

	MDNA	CA Biotechs	CA Markt
7D	8.3%	-2.9%	2.2%
1Y	230.5%	-5.4%	23.4%

Rendite im Vergleich zur Industrie: MDNA übertraf die Branche Canadian Biotechs , die im vergangenen Jahr eine Rendite von -5.4 erzielte.

Rendite vs. Markt: MDNA übertraf den Markt Canadian, der im vergangenen Jahr eine Rendite von 23.4 erzielte.

Preisvolatilität

Is MDNA's price volatile compared to industry and market?
MDNA volatility
MDNA Average Weekly Movement	11.9%
Biotechs Industry Average Movement	11.9%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.7%
10% least volatile stocks in CA Market	2.9%

Stabiler Aktienkurs: MDNA hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: MDNADie wöchentliche Volatilität (12%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
n/a	16	Fahar Merchant	www.medicenna.com

Medicenna Therapeutics Corp. ist ein Immuntherapie-Unternehmen, das sich mit der Entwicklung und Vermarktung von Superkinen und verstärkten Superkinen für die Behandlung von Krebs und anderen Krankheiten befasst. Es entwickelt bizaxofusp (MDNA55), ein Interleukin-4 (IL-4) EC für die Behandlung von rezidivierenden Glioblastomen sowie von Hirntumoren. Das Unternehmen entwickelt außerdem MDNA11, eine verbesserte Version von IL-2 zur Aktivierung und Vermehrung von Immunzellen, die zur Krebsbekämpfung benötigt werden; MDNA209, einen IL-2-Antagonisten für Autoimmunerkrankungen wie Multiple Sklerose und Graft-versus-Host-Krankheit; MDNA413, einen dualen IL-4/IL-13-Antagonisten zur Behandlung von Krebsimmuntherapien; MDNA113, ein maskiertes bifunktionales Anti-PD1-IL2-Superkin für verschiedene solide Tumore; und MDNA132, ein IL-13-Superkin für verschiedene Tumore.

Medicenna Therapeutics Corp.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Medicenna Therapeutics im Vergleich zum Marktanteil des Unternehmens?
MDNA grundlegende Statistiken
Marktanteil	CA$122.71m
Gewinn(TTM)	-CA$26.68m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-4.6x

Kurs-Gewinn-Verhältnis

Ist MDNA zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
MDNA Gewinn- und Verlustrechnung (TTM)
Einnahmen	CA$0
Kosten der Einnahmen	CA$0
Bruttogewinn	CA$0
Sonstige Ausgaben	CA$26.68m
Umsatz	-CA$26.68m

Zuletzt gemeldete Gewinne

Sep 30, 2024

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-0.34
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich MDNA auf lange Sicht entwickelt?

Historische Performance und Vergleiche

MDNA Aktienübersicht

Belohnungen

Risikoanalyse

Medicenna Therapeutics Corp. Wettbewerber

TSX:ONC

CA$102.5m

TSXV:COV

CA$103.8m

TSX:MSCL

CA$85.2m

TSX:EPRX

CA$174.9m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Recent updates

Medicenna Therapeutics Corp. Announces Positive Single-Agent Activity of MDNA11 from Dose Expansion Cohort and Encouraging Safety Profile in Combination with KEYTRUDA® (Pembrolizumab) at the 39th Annual Meeting of SITC

Medicenna Therapeutics Corp. Presents Preclinical Data from Its Anti-PD1-IL-2 BiSKIT and IL-2 Super Agonist Programs At the 39Th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Presents Preclinical Results from Its IL-2 Super-Antagonist and Anti -PD1-IL-2 Biskit Programs At the Promise of Interleukin-2 Therapy Conference

Medicenna Therapeutics Corp. Appoints Mr. Karim Lalji as New Addition to its Board of Directors

Medicenna Therapeutics Corp., Annual General Meeting, Sep 26, 2024

Medicenna Therapeutics Corp. Announces Ema Approval of Its Clinical Trial Application to Expand Its Phase 1/2 Ability-1 Study to Europe

Medicenna Therapeutics Presents Positive Survival Data for Bizaxofusp in Phase 2B Study At Asco 2024

Medicenna Therapeutics Files Form 15

Medicenna Therapeutics Corp. announced that it has received CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. announced that it expects to receive CAD 20 million in funding from RA Capital Management, L.P.

Medicenna Therapeutics Corp. Presents Updated Results of Single Agent MDNA11 Anti-Tumor Activity from Dose Escalation and Ongoing Dose Expansion of the Phase 1/2 ABILITY-1 Study

Medicenna to Provide Clinical Update on the Mdna11 Ability-1 Trial At the Upcoming American Association for Cancer Research Annual Meeting

Medicenna Therapeutics Corp. Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with Keytruda® (Pembrolizumab) in Patients with Advanced Solid Tumors

Medicenna Therapeutics Corp. Announces Initiation of Enrollment in Combination Arm of Phase 1/2 ABILITY Study Evaluating MDNA11 with Merck’s Pembrolizumab

Medicenna Therapeutics Corp. Announces A Poster Presentation and an Oral Summary Highlighting Long-term Follow-up Up Results from the Phase 2b Clinical Trial of Bizaxofusp

Medicenna Therapeutics Corp. to Present 4 Year Follow-Up Phase 2B Bizaxofusp Survival Data in Recurrent Glioblastoma At the Society for Neuro-Oncology 2023 Annual Meeting

Medicenna Therapeutics Corp. Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer

Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Medicenna Therapeutics Corp.(NasdaqCM:MDNA) dropped from NASDAQ Composite Index

Medicenna Therapeutics Corp. Announces the Departure of Jeff Caravella as Chief Financial Officer

New major risk - Revenue and earnings growth

Medicenna Therapeutics Corp. Announces Dosing of the First Patient in the Phase 2 Monotherapy Dose Expansion Portion of the Phase 1/2 ABILITY

We Think Medicenna Therapeutics (TSE:MDNA) Needs To Drive Business Growth Carefully

Medicenna Therapeutics Appoints Humphrey Gardner, as Chief Medical Officer

Medicenna Therapeutics Corp. Presents Preclinical MDNA223 BiSKIT Data at the AACR Special Conference on Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. to Present at the AACR Special Conference Cancer Research: Tumor Immunology and Immunotherapy

Medicenna Therapeutics Corp. Announces the Appointment of Jeff Caravella as Chief Financial Officer

Medicenna Therapeutics Corp. Announces Departure of Elizabeth Williams as Chief Financial Officer

Medicenna Therapeutics Corp. Completes MDNA11 Dose Escalation and Commences Monotherapy Dose Expansion in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp. Appoints Dr. Arash Yavari as Chair of Development Advisory Committee

Medicenna Therapeutics Corp., Annual General Meeting, Sep 28, 2023

New minor risk - Share price stability

Medicenna Therapeutics (TSE:MDNA) Is In A Good Position To Deliver On Growth Plans

Companies Like Medicenna Therapeutics (TSE:MDNA) Are In A Position To Invest In Growth

Medicenna Therapeutics Corp. to Report Q3, 2023 Results on Feb 07, 2023

Price target decreased to CA$7.00

High number of new and inexperienced directors

Medicenna Therapeutics Corp. Presents Updated Clinical Data from Dose Escalation Portion of Phase 1/2 Ability Study of Mdna11 At the Sitc Annual Meeting

Here's Why We're Not Too Worried About Medicenna Therapeutics' (TSE:MDNA) Cash Burn Situation

Price target increased to CA$12.00

Medicenna Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Lead Independent Director recently bought CA$74k worth of stock

Medicenna Therapeutics Corp. Confirms Partial Response in Pancreatic Cancer and Clinical Update on MDNA11’s Monotherapy Dose Escalation Portion of the Ongoing Phase 1/2 Ability Study

Medicenna Therapeutics Corp. Presents Preclinical Data Demonstrating Anti-Tumor Activity of Its Anti-Pd1-Il-2 Biskit and Long-Acting Il-4/Il-13 Super-Antagonist At Cytokines 2022

Medicenna Therapeutics Corp. Announces Clinical Collaboration with Merck to evaluate MDNA11 in combination with KEYTRUDA® (pembrolizumab) in ABILITY Trial

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. has completed a Composite Units Offering in the amount of $20.000001 million.

Medicenna Therapeutics Corp. to Report Q1, 2023 Results on Aug 15, 2022

Medicenna Announces New Clinical Data Providing Preliminary Evidence of MDNA11’s Single Agent Anti-Cancer Activity in the Phase 1/2 ABILITY Study

Medicenna Therapeutics Corp., Annual General Meeting, Sep 21, 2022

No longer forecast to breakeven

Price target decreased to CA$10.63

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. to Report Fiscal Year 2022 Results on Jun 22, 2022

Medicenna Therapeutics Corp. Presents Phase 1/2 Ability Study Data Highlighting Mdna11's Favorable Clinical Profile At the 2022 Frontiers in Cancer Immunotherapy Meeting

Medicenna Therapeutics Corp. Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 Ability Study

High number of new and inexperienced directors

Medicenna Announces Preclinical Data Highlighting the Potent Anti-Tumor Efficacy of Anti-PD1-IL-2 BiSKIT at the AACR Annual Meeting

Forecast to breakeven in 2025

Erträge & Einnahmen